The GL-2045 discovery program started when a family member of one of Gliknik’s founders needed IVIG, a synthetic human blood product used to treat disorders of the immune system or to boost immune response to serious illness.
Gliknik selected Pfizer as its pharmaceutical partner for GL-2045 in part because Pfizer best demonstrated its commitment to advance the compound aggressively.
The weekly average number of planned internal meetings at Gliknik is one.
Gliknik’s stradobody™ program for cancer has been supported by a competitively won contract with the National Cancer Institute.
Henrik Olsen was one of the first 10 employees at Human Genome Sciences and stayed there for 10 years.
Scott Strome is the co-inventor of antibody therapeutics to PD-L1, which may be particularly beneficial in helping to treat a range of cancers.
For decades doctors thought a synthetic version of the human blood product, IVIG, couldn’t be made. Gliknik’s synthetic version of IVIG is heading for clinical trials.